“Cost Per Responder Analysis of Guselkumab Versus Adalimumab Using Efficacy Results Fromm a Head-to-Head Clinical Trial in Patients With Moderate to Severe Plaque Psoriasis”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s6. https://doi.org/10.25251/skin.1.supp.5.